Xenon Pharmaceuticals (NASDAQ:XENE) Earns Outperform Rating from William Blair

by · The Cerbat Gem

Xenon Pharmaceuticals (NASDAQ:XENE – Get Free Report)‘s stock had its “outperform” rating reiterated by equities researchers at William Blair in a research note issued on Monday,RTT News reports.

Other analysts have also recently issued research reports about the stock. StockNews.com cut shares of Xenon Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday. HC Wainwright restated a “buy” rating and set a $53.00 price objective on shares of Xenon Pharmaceuticals in a report on Monday, February 24th. The Goldman Sachs Group cut their target price on Xenon Pharmaceuticals from $60.00 to $52.00 and set a “buy” rating on the stock in a research note on Thursday, April 17th. Deutsche Bank Aktiengesellschaft initiated coverage on Xenon Pharmaceuticals in a research report on Tuesday, February 11th. They set a “buy” rating and a $67.00 target price on the stock. Finally, Royal Bank of Canada reaffirmed an “outperform” rating on shares of Xenon Pharmaceuticals in a report on Friday, February 28th. One investment analyst has rated the stock with a sell rating and ten have assigned a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $56.78.

View Our Latest Analysis on Xenon Pharmaceuticals

Xenon Pharmaceuticals Stock Performance

NASDAQ:XENE traded down $0.32 during mid-day trading on Monday, hitting $37.96. The stock had a trading volume of 328,343 shares, compared to its average volume of 453,868. The company’s 50 day simple moving average is $34.74 and its 200 day simple moving average is $38.53. Xenon Pharmaceuticals has a twelve month low of $26.74 and a twelve month high of $46.00. The stock has a market cap of $2.91 billion, a price-to-earnings ratio of -13.45 and a beta of 1.21.

Xenon Pharmaceuticals (NASDAQ:XENE – Get Free Report) last released its earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.84) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.89) by $0.05. As a group, equities analysts forecast that Xenon Pharmaceuticals will post -3.1 earnings per share for the current year.

Hedge Funds Weigh In On Xenon Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of XENE. GF Fund Management CO. LTD. purchased a new position in Xenon Pharmaceuticals during the 4th quarter valued at about $63,000. Quarry LP purchased a new position in shares of Xenon Pharmaceuticals during the fourth quarter valued at approximately $78,000. Blue Trust Inc. raised its holdings in shares of Xenon Pharmaceuticals by 140.3% during the fourth quarter. Blue Trust Inc. now owns 2,422 shares of the biopharmaceutical company’s stock valued at $95,000 after acquiring an additional 1,414 shares in the last quarter. Avior Wealth Management LLC purchased a new stake in Xenon Pharmaceuticals in the fourth quarter worth $101,000. Finally, KBC Group NV boosted its holdings in Xenon Pharmaceuticals by 39.8% in the fourth quarter. KBC Group NV now owns 2,742 shares of the biopharmaceutical company’s stock valued at $107,000 after acquiring an additional 780 shares in the last quarter. 95.45% of the stock is owned by institutional investors.

Xenon Pharmaceuticals Company Profile

(Get Free Report)

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.

Featured Articles